Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ Rx Comparisons Should Focus On Existing Literature, Not Clinical Trials, McClellan Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Clinical trials take too much time and money, CMS Administrator McClellan says. Programs mandated under Medicare Rx law, such as the chronic care improvement pilot and the Part B replacement drug demo, will provide clinical data to evaluate comparative effectiveness, he says.

You may also be interested in...



AHRQ Research Priorities Should Include Quality Of Cardiovascular Care, Guidant Says

The agency should research a potential disparity in cardiovascular care between men and women, and the clinical and economic benefits of early screening for carotid artery disease, Guidant says. The device industry has also raised new technology underutilization and e-health as potential topics.

AHRQ Research Priorities Should Include Quality Of Cardiovascular Care, Guidant Says

The agency should research a potential disparity in cardiovascular care between men and women, and the clinical and economic benefits of early screening for carotid artery disease, Guidant says. The device industry has also raised new technology underutilization and e-health as potential topics.

AHRQ Rx Comparative Research Partners Include CMS, NIH, FDA, VA, McClellan Says

CMS administrator says NIH can develop comparative evidence based on clinical trial databases and keep CMS apprised of drugs being studied. Speakers at AHRQ comparative research “town hall” point to public, private and international purchasers that could provide comparative drug information.

Related Content

Topics

UsernamePublicRestriction

Register

PS059483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel